{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:53:50Z","timestamp":1777632830718,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tyrosine kinase inhibitor treatment of chronic myeloid leukemia (CML) has demonstrated beneficial effects. However, resistance to tyrosine kinase inhibitors and disease relapse are still a challenge for CML therapy. In this study, we analyzed bone marrow samples from 149 CML patients and 15 control donors, and investigated the affect of AF1q on CML cell survival and engraftment in vitro and in vivo. We found that <jats:italic>AF1q\/MLLT11<\/jats:italic> expression was significantly upregulated in CML patients, especially in CD34<jats:sup>+<\/jats:sup> CML cells. Elevated AF1q expression was associated with disease progression. Knockdown of AF1q enhanced imatinib sensitivity, induced apoptosis, and suppressed growth in CML cells. Moreover, AF1q deficiency sensitized CD34<jats:sup>+<\/jats:sup> CML cells to imatinib. In contrast, upregulation of AF1q promoted cell survival, protected CML cells from imatinib-induced apoptosis, and increased engraftment of CML cells in vivo. We further identified a positive correlation between <jats:italic>AF1q<\/jats:italic> and <jats:italic>CD44<\/jats:italic> expression in chronic phase CML patients and CD34<jats:sup>+<\/jats:sup> CML cells. Importantly, AF1q contributes to imatinib-resistance in CML by regulating the expression of CD44. These findings reveal a novel BCR-ABL-independent pathway, AF1q\/CD44, involves imatinib resistance in CML, thus representing a potential therapeutic target for imatinib-resistant CML patients.<\/jats:p>","DOI":"10.1038\/s41419-018-0900-7","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T21:03:51Z","timestamp":1535490231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel AF1q\/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia"],"prefix":"10.1038","volume":"9","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihua","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaolei","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman, J. M. & Melo, J. V. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451\u20131464 (2003).","journal-title":"N. Engl. J. Med."},{"key":"900_CR2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343\u20133356 (2000).","journal-title":"Blood"},{"key":"900_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172\u2013183 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","volume":"124","author":"P Gallipoli","year":"2014","unstructured":"Gallipoli, P. et al. JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34\u2009+\u2009cells in vitro and in vivo. Blood 124, 1492\u20131501 (2014).","journal-title":"Blood"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"900_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","volume":"29","author":"J Cortes","year":"2011","unstructured":"Cortes, J., Hochhaus, A., Hughes, T. & Kantarjian, H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J. Clin. Oncol. 29, 524\u2013531 (2011).","journal-title":"J. Clin. Oncol."},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa, J. et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2, e528\u2013e535 (2015).","journal-title":"Lancet Haematol."},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013).","journal-title":"Blood"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038\u20131042 (2001).","journal-title":"N. Engl. J. Med."},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2014-01-547943","volume":"123","author":"MY Hsieh","year":"2014","unstructured":"Hsieh, M. Y. & Van Etten, R. A. IKK-dependent activation of NF-kappaB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood 123, 2401\u20132411 (2014).","journal-title":"Blood"},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002).","journal-title":"Blood"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011).","journal-title":"J. Clin. Invest."},{"key":"900_CR14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V85.3.650.bloodjournal853650","volume":"85","author":"W Tse","year":"1995","unstructured":"Tse, W., Zhu, W., Chen, H. S. & Cohen, A. A novel gene, AF1q, fused to MLL in t(1;11) (q21; q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 85, 650\u2013656 (1995).","journal-title":"Blood"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1182\/blood-2011-01-333179","volume":"118","author":"A Parcelier","year":"2011","unstructured":"Parcelier, A. et al. AF1q\/MLLT11 regulates the emergence of human prothymocytes through cooperative interaction with the Notch signaling pathway. Blood 118, 1784\u20131796 (2011).","journal-title":"Blood"},{"key":"900_CR16","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2003-12-4347","volume":"104","author":"W Tse","year":"2004","unstructured":"Tse, W. et al. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104, 3058\u20133063 (2004).","journal-title":"Blood"},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ajh.21396","volume":"84","author":"CJ Strunk","year":"2009","unstructured":"Strunk, C. J. et al. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am. J. Hematol. 84, 308\u2013309 (2009).","journal-title":"Am. J. Hematol."},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1365-2141.2004.05306.x","volume":"128","author":"W Tse","year":"2005","unstructured":"Tse, W. et al. Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br. J. Haematol. 128, 218\u2013220 (2005).","journal-title":"Br. J. Haematol."},{"key":"900_CR19","doi-asserted-by":"crossref","unstructured":"Park J. et al. MLLT11\/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. Oncotarget. 7, 43960\u201343973 (2016).","DOI":"10.18632\/oncotarget.9759"},{"key":"900_CR20","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.18632\/oncotarget.4136","volume":"6","author":"J Park","year":"2015","unstructured":"Park, J. et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget 6, 20697\u201320710 (2015).","journal-title":"Oncotarget"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-007-9761-y","volume":"111","author":"XZ Chang","year":"2008","unstructured":"Chang, X. Z. et al. Identification of the functional role of AF1Q in the progression of breast cancer. Breast Cancer Res. Treat. 111, 65\u201378 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1016\/j.ejca.2006.07.008","volume":"42","author":"DQ Li","year":"2006","unstructured":"Li, D. Q. et al. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur. J. Cancer 42, 3274\u20133286 (2006).","journal-title":"Eur. J. Cancer"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1210\/jc.2004-1337","volume":"90","author":"C Jacques","year":"2005","unstructured":"Jacques, C. et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J. Clin. Endocrinol. Metab. 90, 2314\u20132320 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"900_CR24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00018-015-2108-7","volume":"73","author":"Y Hu","year":"2016","unstructured":"Hu, Y. & Li, S. Survival regulation of leukemia stem cells. Cell. Mol. Life Sci. 73, 1039\u20131050 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"900_CR25","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/nm1489","volume":"12","author":"DS Krause","year":"2006","unstructured":"Krause, D. S., Lazarides, K., von Andrian, U. H. & Van Etten, R. A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12, 1175\u20131180 (2006).","journal-title":"Nat. Med."},{"key":"900_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-117","volume":"13","author":"G Chang","year":"2013","unstructured":"Chang, G. et al. CD44 targets Wnt\/beta-catenin pathway to mediate the proliferation of K562 cells. Cancer Cell Int. 13, 117 (2013).","journal-title":"Cancer Cell Int."},{"key":"900_CR27","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F. & Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167\u20131174 (2006).","journal-title":"Nat. Med."},{"key":"900_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/leu.2010.281","volume":"25","author":"R Quere","year":"2011","unstructured":"Quere, R. et al. High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 25, 515\u2013526 (2011).","journal-title":"Leukemia"},{"key":"900_CR29","doi-asserted-by":"publisher","first-page":"15444","DOI":"10.1073\/pnas.1506943112","volume":"112","author":"F Holm","year":"2015","unstructured":"Holm, F. et al. Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal. Proc. Natl Acad. Sci. USA 112, 15444\u201315449 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"900_CR30","first-page":"235","volume":"6","author":"M Zoller","year":"2015","unstructured":"Zoller, M. CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells. Front. Immunol. 6, 235 (2015).","journal-title":"Front. Immunol."},{"key":"900_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0145-2126(96)00048-3","volume":"20","author":"S Khaldoyanidi","year":"1996","unstructured":"Khaldoyanidi, S., Achtnich, M., Hehlmann, R. & Zoller, M. Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression. Leuk. Res. 20, 839\u2013851 (1996).","journal-title":"Leuk. Res."},{"key":"900_CR32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/leu.2016.20","volume":"30","author":"MB Miranda","year":"2016","unstructured":"Miranda, M. B. et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia 30, 1255\u20131262 (2016).","journal-title":"Leukemia"},{"key":"900_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1615\/CritRevOncog.v17.i1.30","volume":"17","author":"DT Yeung","year":"2012","unstructured":"Yeung, D. T. & Hughes, T. P. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit. Rev. Oncog. 17, 17\u201330 (2012).","journal-title":"Crit. Rev. Oncog."},{"key":"900_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-2141.2011.08662.x","volume":"153","author":"Y Xiong","year":"2011","unstructured":"Xiong, Y. et al. MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br. J. Haematol. 153, 753\u2013757 (2011).","journal-title":"Br. J. Haematol."},{"key":"900_CR35","doi-asserted-by":"publisher","first-page":"e39968","DOI":"10.1371\/journal.pone.0039968","volume":"7","author":"P Tiberio","year":"2012","unstructured":"Tiberio, P., Cavadini, E., Callari, M., Daidone, M. G. & Appierto, V. AF1q: a novel mediator of basal and 4-HPR-induced apoptosis in ovarian cancer cells. PLoS ONE 7, e39968 (2012).","journal-title":"PLoS ONE"},{"key":"900_CR36","first-page":"547","volume":"24","author":"NN Co","year":"2010","unstructured":"Co, N. N. et al. AF1q enhancement of gamma irradiation-induced apoptosis by up-regulation of BAD expression via NF-kappaB in human squamous carcinoma A431 cells. Oncol. Rep. 24, 547\u2013554 (2010).","journal-title":"Oncol. Rep."},{"key":"900_CR37","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1158\/1535-7163.MCT-08-0416","volume":"7","author":"NN Co","year":"2008","unstructured":"Co, N. N. et al. Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway. Mol. Cancer Ther. 7, 3160\u20133168 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"900_CR38","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","volume":"9","author":"E Nicholson","year":"2009","unstructured":"Nicholson, E. & Holyoake, T. The chronic myeloid leukemia stem cell. Clin. Lymphoma Myeloma 9, S376\u2013S381 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"900_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/leu.2008.246","volume":"23","author":"N Misaghian","year":"2009","unstructured":"Misaghian, N. et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23, 25\u201342 (2009).","journal-title":"Leukemia"},{"key":"900_CR40","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501\u20131510 (2012).","journal-title":"Blood"},{"key":"900_CR41","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1172\/JCI44540","volume":"121","author":"RL Brown","year":"2011","unstructured":"Brown, R. L. et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 121, 1064\u20131074 (2011).","journal-title":"J. Clin. Invest."},{"key":"900_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-418","volume":"11","author":"E Olsson","year":"2011","unstructured":"Olsson, E. et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11, 418 (2011).","journal-title":"BMC Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0900-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:04:06Z","timestamp":1671537846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0900-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,28]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0900-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,28]]},"assertion":[{"value":"15 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"855"}}